Skip to main content

Table 1 Risk of amputation, PAD and DF events in patients with SGLT2i treatment

From: Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis

Subgroup No. of participants (SGLT2i/control) OR 95% CI P value I2 (%)
Risk of amputation by SGLT2i subtypes
 In total* 40,765/33,406 1.21 1.06, 1.37 0.004 4
 Canagliflozin* 7990/6541 1.60 1.04, 2.46 0.03 67
 Dapagliflozin 13,236/13,234 1.05 0.85, 1.30 0.66 0
 Empagliflozin 7101/4463 1.07 0.76, 1.49 0.71 0
 Ertugliflozin 5493/2745 1.24 0.87, 1.76 0.23 NA
 Sotagliflozin 6945/6423 1.08 0.68, 1.70 0.75 0
Risk of amputation by study types
 CVOT and ROT* 39,020/32,465 1.20 1.06, 1.37 0.005 30
 Efficacy and safety evaluation 1745/941 1.80 0.36, 8.95 0.47 0
Risk of amputation by population
 DM only* 34,715/27,194 1.24 1.08, 1.42 0.002 15
 Including patients without DM 6380/6380 1.00 0.70, 1.43 1.00 0
Risk of amputation by control types
 Active agent 551/267 1.46 0.06, 35.90 0.82 NA
 Placebo* 40,214/33,139 1.21 1.06, 1.37 0.004 11
Risk of amputation by study duration (weeks)
 < 26 145/148 3.08 0.12, 76.30 0.49 NA
 26–52 2205/1404 2.34 0.58, 9.52 0.23 0
 > 52* 38,415/31,854 1.20 1.05, 1.36 0.006 31
Risk of PAD by SGLT2i subtypes
 In total* 36,701/28,676 1.21 1.03, 1.42 0.02 0
 Canagliflozin* 10,465/7965 1.53 1.14, 2.05 0.005 0
 Dapagliflozin 15,821/14,655 1.02 0.81, 1.29 0.85 0
 Empagliflozin 8111/4560 1.25 0.88, 1.78 0.21 0
 Ertugliflozin 1605/793 1.49 0.30, 7.42 0.62 0
 Sotagliflozin 699/703 0.33 0.01, 8.23 0.50 NA
Risk of PAD by study types
 CVOT and ROT* 25,768/21,960 1.24 1.05, 1.46 0.01 6
 Efficacy and safety evaluation 10,933/6716 0.94 0.54, 1.63 0.82 0
Risk of PAD by population
 DM only* 32,184/24,159 1.22 1.03, 1.45 0.02 0
 Including patients without DM 4517/4517 1.10 0.67, 1.79 0.71 0
Risk of PAD by control types
 Active agent 3847/2611 1.00 0.33, 3.06 1.00 0
 Placebo* 32,854/26065 1.21 1.03, 1.43 0.02 0
Risk of PAD by study duration (weeks)
 < 26 5114/3162 0.90 0.43, 1.89 0.78 0
 26–52 2855/1717 1.62 0.48, 5.52 0.44 0
 > 52* 28,632/23,797 1.22 1.03, 1.44 0.02 0
Risk of DF by SGLT2i subtypes
 In total 32,043/25558 1.23 0.93, 1.63 0.15 0
 Canagliflozin 9137/7113 1.55 0.94, 2.54 0.09 0
 Dapagliflozin 14,586/13,806 1.20 0.79, 1.82 0.40 0
 Empagliflozin 7127/4055 0.89 0.48, 1.65 0.71 0
 Ertugliflozin 1193/584 1.48 0.15, 14.23 0.74 0
Risk of DF by study types
 CVOT and ROT 25,768/21,960 1.23 0.91, 1.66 0.17 0
 Efficacy and safety evaluation 6275/3598 1.23 0.53, 2.84 0.63 0
Risk of DF by population
 DM only 27,526/21,041 1.27 0.95, 1.71 0.11 0
 Including patients without DM 4517/4517 0.89 0.34, 2.31 0.81 0
Risk of DF by control types
 Active agent 4164/2459 1.53 0.44, 5.33 0.50 0
 Placebo 27,879/23,099 1.22 0.91, 1.63 0.18 0
Risk of DF by study duration (weeks)
 < 26 1183/562 1.45 0.23, 9.22 0.69 0
 26–52 3029/1606 1.45 0.42, 4.93 0.56 0
 > 52 27,831/23,390 1.22 0.91, 1.63 0.19 0
  1. PAD peripheral arterial disease, SGLT2i sodium glucose co-transporter 2 inhibitor, DF diabetic foot, DM diabetes mellitus, CVOT cardiovascular outcome trial, ROT renal outcome trial, OR odd ratio, CI confidence interval, NA not applicable
  2. *P < 0.05